Roche partners with Defand: Roche Holding stock pre-market at EUR 381.98, plus 0.29 percent
Published on 10/09/2026 at 08:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Roche is partnering with Defand Therapeutics on molecular glue medicines.
- Roche Holding stock was at EUR 381.98 pre-market at Lang & Schwarz.
- The price was up 0.29 percent versus the EUR 380.88 prior close.
Defand Therapeutics said it signed a collaboration deal with Roche on October 8, 2026, to discover molecular glue medicines for cancer and immune-driven diseases. At Lang & Schwarz, Roche Holding stock was at EUR 381.98 pre-market at 8:20 a.m. CEST on October 9, 2026, up 0.29 percent versus the EUR 380.88 prior close of October 8, 2026.
Roche stock before the Xetra open
The Lang & Schwarz bid was EUR 381.25 and the ask was EUR 382.70 at 8:20 a.m. CEST on October 9, 2026. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Roche Holding stock.
Collaboration focuses on molecular glue medicines
STAT reported that Defand will discover and develop multiple medicines under the agreement, while Roche is enlisting the Chinese startup to discover new drugs rather than licensing existing clinical-stage medicines. The report said the financial terms were not disclosed.
Defand’s announcement described the research focus as molecular glue therapies for oncology and immunology, according to the report. The companies’ collaboration is dated October 8, 2026.
Market context: Market report SMI.
